Cellectar Biosciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

STOCK-BASED COMPENSATION (Tables)

STOCK-BASED COMPENSATION (Tables)

3 Months Ended

Mar. 31, 2022

STOCK-BASED COMPENSATION

Schedule of Accounting for Stock-Based Compensation


		Three Months Ended
		March 31,
		2022			2021

Employee and director stock option grants:
Research and development		$	41,928		$	29,395
General and administrative			261,877			95,169
Total stock-based compensation		$	303,805		$	124,564

Schedule of Stock Options Activity

A summary of stock option activity is as follows:


							Weighted
		Number of					Average
		Shares Issuable					Remaining
		Upon Exercise		Weighted			Contracted		Aggregate
		of Outstanding		Average			Term in		Intrinsic
		Options		Exercise Price			Years		Value
Outstanding at December 31, 2021		4,238,200		$	2.27				$	—
Granted		2,778,500		$	0.55
Forfeited		(952,000)		$	1.86
Outstanding at March 31, 2022		6,064,700		$	1.64		9.03		$	338,910

Exercisable March 31, 2022		1,555,630		$	3.33		7.94		$	—
Unvested, March 31, 2022		4,509,070		$	1.05		9.41		$	338,910